Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report?
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Allergan (AGN). This company, which is in the Zacks Medical - Generic Drugs industry, shows potential for another earnings beat.
When looking at the last two reports, this Botox maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 4.68%, on average, in the last two quarters.
For the most recent quarter, Allergan was expected to post earnings of $4.15 per share, but it reported $4.29 per share instead, representing a surprise of 3.37%. For the previous quarter, the consensus estimate was $4.01 per share, while it actually produced $4.25 per share, a surprise of 5.99%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Allergan. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Allergan has an Earnings ESP of +0.41% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner.
When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Click to get this free report
Allergan plc (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.